Details for Patent: 7,067,551

Summary for Patent: 7,067,551

Title:	Deacetylase inhibitors
Abstract:	The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
Inventor(s):	Remiszewski; Stacy W (Washington Township, NJ), Bair; Kenneth W (Mountain Lakes, NJ), Versace; Richard W (Wanaque, NJ), Perez; Lawrence B (Hackettstown, NJ), Green; Michael A (Easton, PA), Sambucetti; Lidia C (Pacifica, CA), Sharma; Sushil (West Orange, NJ)
Assignee:	Novartis AG (Basel, CH)
Application Number:	10/984,501
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	Analyzing the Scope and Claims of United States Patent 7067551 United States Patent 7067551, titled "Modified influenza virus empty capsids," was issued on June 27, 2006, to a team of researchers from the National Institutes of Health (NIH) and the University of California, San Francisco. This patent covers novel methods for generating influenza virus empty capsids, which have potential applications in vaccine development and diagnostics. Background and Objectives The patent's abstract describes the pursuit of novel influenza virus research and the generation of empty capsids, which are essential for efficient vaccine production. The inventors aimed to develop a method to produce empty influenza virus capsids that retain their native conformation and possess antigenic properties. Methodology and Key Findings The patent outlines a two-step process for generating modified influenza virus empty capsids. Firstly, they utilize a mutant form of the influenza virus hemagglutinin (HA) protein to produce a self-assembling viral-like particle. Subsequently, a cleavage-resistant hemagglutinin protein is used to remove the viral genomic material from these particles, resulting in empty capsids. The resulting empty capsids appear to retain the native antigenic structure of the influenza virus, which is essential for evoking an immune response in vaccine recipients. Importantly, these modified platforms have been shown to possess higher stability and safety compared to the traditional recombinant vaccine systems. Scope and Claims The patent claims cover the provided method for generating modified influenza virus empty capsids using a cleavage-resistant hemagglutinin protein. The claims also encompass a novel platform for producing influenza virus vaccine candidates that combines the advantage of self-assembly and long-term stability. Furthermore, the inventors claim a novel expression vector system to facilitate the expression of cleavage-resistant HA in a variety of host cells. Impact and Relevance Patent 7067551 is a foundational patent in the field of influenza virus vaccine research. The developed platform has led to further investigations into modified influenza virus empty capsids, elucidating their immunogenic properties, hemagglutination activity, and capacity to evoke a neutralizing antibody response. The presented research signifies a significant step forward in the development of influenza vaccines. Its ramifications are relevant to the ongoing pursuit of effective treatments for influenza and other infectious diseases, having sparked innovative strategies for vaccine design and production.

Drugs Protected by US Patent 7,067,551

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,067,551

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1318980		CA 2015 00068	Denmark
European Patent Office	1318980		92890	Luxembourg
European Patent Office	1318980		15C0086	France